RALGAPA2

Summary

RALGAPA2 (Ral GTPase activating protein catalytic subunit alpha 2, HGNC:16207) is a protein-coding gene on chromosome 20p11.23, encoding Ral GTPase-activating protein subunit alpha-2 (Q2PPJ7). Catalytic subunit of the heterodimeric RalGAP2 complex which acts as a GTPase activator for the Ras-like small GTPases RALA and RALB.

Predicted to enable GTPase activator activity and protein heterodimerization activity. Predicted to be involved in activation of GTPase activity. Predicted to act upstream of or within Ral protein signal transduction; regulation of exocyst localization; and regulation of protein localization. Located in cytosol and plasma membrane.

Source: NCBI Gene 57186 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 342 total
• MANE Select transcript: NM_020343

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16207
Approved symbol	RALGAPA2
Name	Ral GTPase activating protein catalytic subunit alpha 2
Location	20p11.23
Locus type	gene with protein product
Status	Approved
Aliases	dJ1049G11.4, AS250, KIAA1272, RapGAPalpha2
Ensembl gene	ENSG00000188559
Ensembl biotype	protein_coding
OMIM	618836
Entrez	57186

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 retained_intron

ENST00000202677, ENST00000424981, ENST00000427175, ENST00000430436, ENST00000495793, ENST00000909985, ENST00000934890

RefSeq mRNA: 1 — MANE Select: NM_020343 NM_020343

CCDS: CCDS46584

Canonical transcript exons

ENST00000202677 — 40 exons

Exon	Start	End
ENSE00000660809	20505411	20505534
ENSE00000660811	20512513	20513284
ENSE00000660812	20520917	20521100
ENSE00000660813	20524406	20524543
ENSE00000660815	20526252	20526362
ENSE00000660816	20531687	20531795
ENSE00000660817	20535745	20535803
ENSE00000660831	20620463	20620630
ENSE00000660832	20629363	20629590
ENSE00000660833	20635418	20635617
ENSE00000859385	20495117	20495275
ENSE00000859386	20503351	20503506
ENSE00000859388	20511254	20511325
ENSE00000859392	20524830	20524898
ENSE00000859395	20536656	20536784
ENSE00001129850	20611315	20611426
ENSE00001205419	20616043	20616191
ENSE00001205422	20619277	20619414
ENSE00001205533	20412027	20412148
ENSE00001205551	20472829	20472956
ENSE00001355068	20546704	20546832
ENSE00001355074	20571458	20571613
ENSE00001355081	20572875	20573068
ENSE00001355086	20583050	20583226
ENSE00001355090	20584865	20584955
ENSE00001419247	20591177	20591314
ENSE00001419835	20589268	20589365
ENSE00001423408	20571848	20571946
ENSE00001543599	20396695	20396734
ENSE00001594292	20680691	20680801
ENSE00001603329	20640701	20640878
ENSE00001611596	20676236	20676288
ENSE00001640410	20653530	20653587
ENSE00001771711	20712375	20712644
ENSE00001774992	20389530	20393253
ENSE00001787953	20643506	20643549
ENSE00003621170	20601682	20601846
ENSE00003631257	20605175	20605412
ENSE00003708180	20639785	20639900
ENSE00003710422	20637363	20637501

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 95.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.4276 / max 279.1550, expressed in 1632 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186594	10.4276	1632

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibialis anterior	UBERON:0001385	95.29	gold quality
sperm	CL:0000019	95.06	gold quality
pancreatic ductal cell	CL:0002079	94.79	gold quality
deltoid	UBERON:0001476	93.77	gold quality
nasal cavity epithelium	UBERON:0005384	93.57	gold quality
ileal mucosa	UBERON:0000331	92.88	gold quality
upper arm skin	UBERON:0004263	92.62	gold quality
visceral pleura	UBERON:0002401	92.33	gold quality
bronchial epithelial cell	CL:0002328	92.28	gold quality
buccal mucosa cell	CL:0002336	91.95	gold quality
bronchus	UBERON:0002185	91.93	gold quality
vastus lateralis	UBERON:0001379	91.87	gold quality
skeletal muscle tissue	UBERON:0001134	91.66	gold quality
quadriceps femoris	UBERON:0001377	91.59	gold quality
skeletal muscle organ	UBERON:0014892	90.46	gold quality
gastrocnemius	UBERON:0001388	90.42	gold quality
trabecular bone tissue	UBERON:0002483	90.38	gold quality
muscle of leg	UBERON:0001383	90.18	gold quality
muscle tissue	UBERON:0002385	90.16	gold quality
ganglionic eminence	UBERON:0004023	89.53	gold quality
embryo	UBERON:0000922	89.52	gold quality
kidney epithelium	UBERON:0004819	89.46	silver quality
ventricular zone	UBERON:0003053	89.34	gold quality
biceps brachii	UBERON:0001507	89.33	gold quality
mucosa of paranasal sinus	UBERON:0005030	89.13	gold quality
parotid gland	UBERON:0001831	88.97	gold quality
sural nerve	UBERON:0015488	88.75	gold quality
liver	UBERON:0002107	88.69	gold quality
pylorus	UBERON:0001166	88.68	gold quality
blood	UBERON:0000178	88.58	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	35.34
E-CURD-119	yes	17.22
E-MTAB-6678	yes	13.72
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

143 targeting RALGAPA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3529-3P	99.90	73.55	3045

Literature-anchored findings (GeneRIF, showing 5)

• The cDNA sequence for human AS250 is reported, and the sites that undergo phosphorylation upon insulin treatment of adipocytes have been identified by tandem mass spectrometry. (PMID:16490346)
• Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. (PMID:22450745)
• loss of RalGAP function has a distinct role in promoting progression from prostatic intraepithelial neoplasia to invasive adenocarcinoma. (PMID:31058283)
• Low RalGAPalpha2 expression was associated with a reduced survival rate in patients with oral squamous cell carcinoma (PMID:31329042)
• The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer. (PMID:32880825)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ralgapa2	ENSDARG00000005861
mus_musculus	Ralgapa2	ENSMUSG00000037110
rattus_norvegicus	Ralgapa2	ENSRNOG00000036964
drosophila_melanogaster	CG5521	FBGN0039466
caenorhabditis_elegans	hgap-1	WBGENE00021209

Paralogs (2): TSC2 (ENSG00000103197), RALGAPA1 (ENSG00000174373)

Protein

Protein identifiers

Ral GTPase-activating protein subunit alpha-2 — Q2PPJ7 (reviewed: Q2PPJ7)

Alternative names: 250 kDa substrate of Akt, p220

All UniProt accessions (4): A0A3B3IS41, Q2PPJ7, H7BZA8, H7C1F9

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of the heterodimeric RalGAP2 complex which acts as a GTPase activator for the Ras-like small GTPases RALA and RALB.

Subunit / interactions. Component of the heterodimeric RalGAP2 complex with RALGAPB. Heterodimerization is required for activity.

Subcellular location. Cytoplasm.

Isoforms (3)

UniProt ID	Names	Canonical?
Q2PPJ7-1	1	yes
Q2PPJ7-2	2
Q2PPJ7-3	3

RefSeq proteins (1): NP_065076* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000331	Rap/Ran_GAP_dom	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR027107	Tuberin/Ral-act_asu	Family
IPR035974	Rap/Ran-GAP_sf	Homologous_superfamily
IPR046859	RGPA/RALGAPB_N	Domain

Pfam: PF02145, PF20412

UniProt features (24 total): modified residue 9, compositionally biased region 6, region of interest 3, splice variant 2, chain 1, domain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9QU1	X-RAY DIFFRACTION	2.72
9QWP	ELECTRON MICROSCOPY	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2PPJ7-F1	72.97	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 373, 376, 379, 486, 696, 715, 820, 821, 1593

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane

MSigDB gene sets: 113 (showing top): WANG_CLIM2_TARGETS_UP, GOBP_ACTIVATION_OF_GTPASE_ACTIVITY, GOBP_REGULATION_OF_GTPASE_ACTIVITY, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, REACTOME_MEMBRANE_TRAFFICKING, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOMF_PROTEIN_HETERODIMERIZATION_ACTIVITY, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, NUYTTEN_NIPP1_TARGETS_DN

GO Biological Process (6): Ral protein signal transduction (GO:0032484), regulation of protein localization (GO:0032880), regulation of small GTPase mediated signal transduction (GO:0051056), regulation of exocyst localization (GO:0060178), activation of GTPase activity (GO:0090630), positive regulation of GTPase activity (GO:0043547)

GO Molecular Function (3): GTPase activator activity (GO:0005096), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Membrane Trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
small GTPase-mediated signal transduction	2
regulation of localization	2
GTPase activity	2
cellular anatomical structure	2
intracellular protein localization	1
regulation of intracellular signal transduction	1
exocyst localization	1
positive regulation of GTPase activity	1
regulation of GTPase activity	1
positive regulation of hydrolase activity	1
enzyme activator activity	1
GTPase regulator activity	1
protein dimerization activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RALGAPA2	CFAP61	Q8NHU2	495
RALGAPA2	RALGAPB	Q86X10	483
RALGAPA2	SLC25A13	Q9UJS0	448
RALGAPA2	SPMAP2L	P0DJG4	441
RALGAPA2	FYB2	Q5VWT5	417
RALGAPA2	CFAP418	Q96NL8	409
RALGAPA2	SLC25A5	P05141	404
RALGAPA2	RALA	P11233	400
RALGAPA2	NFX1	Q12986	388
RALGAPA2	SLC34A2	O95436	374
RALGAPA2	DCDC2C	A8MYV0	360
RALGAPA2	ORMDL2	Q53FV1	356
RALGAPA2	ACOT8	O14734	352
RALGAPA2	ARHGAP4	P98171	350
RALGAPA2	MYEOV	Q96EZ4	338

IntAct

19 interactions, top by confidence:

A	B	Type	Score
RALGAPA2	DDI1	psi-mi:“MI:0915”(physical association)	0.560
GFOD1	PER1	psi-mi:“MI:0914”(association)	0.530
GFOD1	RALGAPA2	psi-mi:“MI:0914”(association)	0.530
NKIRAS2	RALGAPA2	psi-mi:“MI:0914”(association)	0.530
BMI1	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
NKIRAS2	RAP1GDS1	psi-mi:“MI:0914”(association)	0.350
DPH7	CCT2	psi-mi:“MI:0914”(association)	0.350
DLG3	DLG1	psi-mi:“MI:0914”(association)	0.350
MTMR7	RALGAPA2	psi-mi:“MI:0914”(association)	0.350
DPH7	RALGAPA2	psi-mi:“MI:0914”(association)	0.350
GFOD1	SBF1	psi-mi:“MI:0914”(association)	0.350
GFOD1	B4GAT1	psi-mi:“MI:0914”(association)	0.350
NKIRAS2	GABARAPL2	psi-mi:“MI:0914”(association)	0.350
ORF66	RALGAPA1	psi-mi:“MI:0914”(association)	0.350
RALGAPB	DHX15	psi-mi:“MI:0914”(association)	0.350
LAMP1	TRAPPC13	psi-mi:“MI:2364”(proximity)	0.270
RALGAPA2	DDI1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (53): RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Proximity Label-MS), RALGAPA2 (Proximity Label-MS), RALGAPA2 (Proximity Label-MS), RALGAPA2 (Affinity Capture-RNA), RALGAPA2 (Synthetic Lethality), RALGAPA2 (Two-hybrid), RALGAPA2 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS)

ESM2 similar proteins: A0A5F9C6I2, A1L3F5, A2BDA5, A3KGS3, A8E4X8, D3ZXK7, F1R7R1, O75129, P21359, P51593, P97526, Q04690, Q1JPG0, Q2PPJ7, Q3SZD5, Q4QQM5, Q4R5A4, Q5RC14, Q5XPI3, Q5XPI4, Q62717, Q66K64, Q6GLR7, Q6NXD8, Q6P4S8, Q6PFH3, Q6VNB8, Q7L4E1, Q7TMY8, Q7Z6Z7, Q80TJ1, Q86UW7, Q8BHR8, Q8BK03, Q8BYR5, Q8CDG3, Q8CF97, Q8CID0, Q8IY22, Q8IZQ1

Diamond homologs: A3KGS3, O55007, P49815, P86409, P86411, Q2PPJ7, Q3V0G7, Q54SS8, Q61037, Q6GYP7, Q6GYQ0, Q9UUG9, Q9VB98, A2ALS5, A5PF44, G3X9J0, O35412, O43166, O60292, P46062, P47736, Q54EH3, Q55AN8, Q5JCS6, Q5SVL6, Q5VVW2, Q5ZJY3, Q5ZMV8, Q684P5, Q75J96, Q80TE4, Q8C0T5, Q96FS4, Q9P2F8, P49816, Q54TK4

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
RALGAPA2	“form complex”	RalGAP2	binding
AKT2	“down-regulates activity”	RALGAPA2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

342 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	286
Likely benign	12
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

8696 predictions. Top by Δscore:

Variant	Effect	Δscore
20:20412160:G:T	acceptor_gain	1.0000
20:20495112:CGTA:C	donor_loss	1.0000
20:20495113:GTACC:G	donor_loss	1.0000
20:20495114:TA:T	donor_loss	1.0000
20:20495115:A:AC	donor_gain	1.0000
20:20495115:AC:A	donor_gain	1.0000
20:20495116:C:CC	donor_gain	1.0000
20:20495116:CC:C	donor_gain	1.0000
20:20495116:CCT:C	donor_gain	1.0000
20:20495271:CGAAG:C	acceptor_gain	1.0000
20:20495272:GAAG:G	acceptor_gain	1.0000
20:20495273:AAG:A	acceptor_gain	1.0000
20:20495273:AAGCT:A	acceptor_loss	1.0000
20:20495274:AG:A	acceptor_gain	1.0000
20:20495275:GCTGC:G	acceptor_loss	1.0000
20:20495276:C:A	acceptor_loss	1.0000
20:20495276:C:CC	acceptor_gain	1.0000
20:20503346:CTTA:C	donor_loss	1.0000
20:20503347:TTAC:T	donor_loss	1.0000
20:20503349:ACCTT:A	donor_loss	1.0000
20:20503350:C:A	donor_loss	1.0000
20:20503518:C:CT	acceptor_gain	1.0000
20:20503520:C:CT	acceptor_gain	1.0000
20:20505013:TTTG:T	donor_gain	1.0000
20:20505020:T:TA	donor_gain	1.0000
20:20505530:CACGG:C	acceptor_gain	1.0000
20:20505532:CGG:C	acceptor_gain	1.0000
20:20505535:C:CC	acceptor_gain	1.0000
20:20511246:T:A	donor_gain	1.0000
20:20511249:CATA:C	donor_loss	1.0000

AlphaMissense

12324 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:20511278:A:G	L1635P	1.000
20:20495239:A:G	W1749R	0.999
20:20495239:A:T	W1749R	0.999
20:20572982:A:G	W932R	0.999
20:20572982:A:T	W932R	0.999
20:20573009:A:G	W923R	0.999
20:20573009:A:T	W923R	0.999
20:20640845:A:G	W136R	0.999
20:20640845:A:T	W136R	0.999
20:20712389:A:G	L31P	0.999
20:20472871:G:T	A1818D	0.998
20:20495189:A:C	F1765L	0.998
20:20495189:A:T	F1765L	0.998
20:20495191:A:G	F1765L	0.998
20:20495274:A:G	L1737P	0.998
20:20513224:A:G	L1382P	0.998
20:20605295:A:G	W640R	0.998
20:20605295:A:T	W640R	0.998
20:20605397:A:G	W606R	0.998
20:20605397:A:T	W606R	0.998
20:20635507:A:G	W306R	0.998
20:20635507:A:T	W306R	0.998
20:20637486:A:G	W228R	0.998
20:20637486:A:T	W228R	0.998
20:20640866:C:G	G129R	0.998
20:20640866:C:T	G129R	0.998
20:20653548:A:G	W104R	0.998
20:20653548:A:T	W104R	0.998
20:20653580:A:G	L93P	0.998
20:20412137:C:G	R1836P	0.997

dbSNP variants (sampled 300 via entrez): RS1000038343 (20:20654741 T>A), RS1000042763 (20:20521923 T>C), RS1000043963 (20:20455095 T>C), RS1000091645 (20:20654990 G>C), RS1000099160 (20:20540238 A>C), RS1000106147 (20:20582519 A>G), RS1000111133 (20:20709722 C>G), RS1000113168 (20:20495043 C>G,T), RS1000134402 (20:20682032 G>A), RS1000162942 (20:20461866 G>C,T), RS1000168390 (20:20541854 C>A), RS1000188488 (20:20682295 C>T), RS1000226107 (20:20496921 G>A), RS1000227295 (20:20452255 A>C), RS1000247563 (20:20458840 C>A,G,T)

Disease associations

OMIM: gene MIM:618836 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002386_15	Cognitive function	2.000000e-06
GCST008163_382	Height	2.000000e-06
GCST008839_37	Height	7.000000e-09
GCST010136_17	Fruit consumption	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0003925	cognition
EFO:0008111	diet measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3827963	RALGAPA2		0.00	0

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, affects methylation, decreases expression	4
methylmercuric chloride	decreases expression, increases expression	3
Air Pollutants	affects expression, increases abundance, decreases expression	3
Valproic Acid	affects expression, increases expression	3
sodium arsenite	increases abundance, decreases expression	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	increases expression	1
9,10-dihydro-9,10-dihydroxybenzo(a)pyrene	increases expression	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	decreases expression	1
abrine	decreases expression	1
(+)-JQ1 compound	increases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Caffeine	affects phosphorylation	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.